Accueil > Publications > Immunogenomic profiling of the randomized NeoPembrOv clinical trial 2 reveals regulatory T cells and the VEGFR2 angiogenic axis as promising 3 actionable targets to overcome immunoresistance of high-grade ovarian 4 carcinomas
Immunogenomic profiling of the randomized NeoPembrOv clinical trial 2 reveals regulatory T cells and...